An early evaluation of the HISTO SPOT® AB ID Class I & II test in cardiothoracic transplant patients. (21st August 2022)

• Record Type: Journal Article
• Authors: Cashin, James; Flynn, Patrick; Worthington, Judith; Lowe, Marcus; Canterbury, Andrew; Launhardt, Kristin; Crosby, Ian; Sheldon, Stephen; Venkateswaran, Rajamiyer; Poulton, Kay
• Is Part Of: International journal of immunogenetics. Volume 49:Number 5(2022)
• Page Start: 317
• Page End: 324
• Publication Date: 2022-08-21
• Subjects: Cardiothoracic -- CTAG -- HLA antibody screening -- LAB Screen -- Luminex -- Mr. Spot -- Transplantation; Immunogenetics -- Periodicals; 571.9648
• DOI: 10.1111/iji.12595
• Languages: English
• ISSNs: 1744-3121

Abstract

Abstract: The HISTO SPOT ® AB ID assay (BAG Diagnostics GmbH) is a novel single antigen HLA Class I & II antibody definition test used with the MR.SPOT ® processor. We compared this assay with Luminex ® ‐based assays to assess its potential application in defining unacceptable antigens for transplantation in patients awaiting transplants with cardiothoracic organs. A cohort of 40 sensitized cardiothoracic patients were identified, and one sample was selected from each patient. The required screening was based on the patients' antibody profiles (Class I, n = 17, Class II, n = 11, Class I & II, n = 12). Samples were screened with LABScreen™ Single Antigen (SAg), LIFECODES ® LSA™, HISTO SPOT ® AB ID, and an acid modified LABScreen™ SAg test for detecting antibodies against denatured HLA. Results indicated that HISTO SPOT ® AB ID had reduced sensitivity (68% for Class I; 69% for Class II). When compared to LABScreen™ and LIFECODES ®, HISTO SPOT ® AB ID failed to detect Luminex ® ‐defined antibodies with median fluorescence intensity (MFI) ranging from 1114 to 24, 489. The HISTO SPOT ® AB ID panel used in the study had reduced antigen representation compared with Luminex ® ‐based assays which further compromised its capacity for antibody detection and definition. Further work is needed to evaluate the clinical relevance of these differences between the performance of HISTO SPOT ® and Luminex ® ‐based methods.